Literature DB >> 16940890

Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.

Chien-Hua Chen1, Min-Ho Huang, Jee-Chun Yang, Chiu-Kue Nien, Chi-Chieh Yang, Yung-Hsiang Yeh, Sen-Kou Yueh.   

Abstract

BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is rarely reported in Taiwan. GOALS: To determine the prevalence and risk factors of NAFLD in an adult population of Taiwan. STUDY: The cross-sectional community study examined 3245 adults in a rural village of Taiwan. The diagnostic criteria for NAFLD included no excessive alcohol intake, no chronic viral hepatitis, no known etiologies of liver disease, and ultrasonography consistent with fatty liver.
RESULTS: The prevalence of NAFLD was 11.5% (372/3245). The risk factors for NAFLD in the general population were male sex [odds ratio (OR), 1.44; 95% confidence interval (CI), 1.09-1.90], elevated alanine aminotransferase (ALT) (OR, 5.66; 95% CI, 3.99-8.01), obesity (OR, 7.21; 95% CI, 5.29-9.84), fasting plasma glucose > or =126 mg/dL (OR, 2.08; 95% CI, 1.41-3.05), total cholesterol > or =240 mg/dL (OR, 1.50; 95% CI, 1.06-2.13), triglyceride > or =150 mg/dL (OR, 1.76; 95% CI, 1.32-2.35), and hyperuricemia (OR, 1.53; 95% CI, 1.16-2.01). Age > or =65 years was inversely related to NAFLD (OR, 0.53; 95% CI, 0.36-0.77). The only NAFLD risk factors among nonobese subjects were age between 40 and 64 years (OR, 2.35; 95% CI, 1.34-4.11, P=0.003), elevated ALT (OR, 15.45; 95% CI, 8.21-29.09, P<0.001), and triglyceride > or =150 mg/dL (OR, 2.48; 95% CI, 1.42-4.32, P=0.001). In subjects with NAFLD, the prevalence of elevated ALT in the presence of each metabolic risk factor, such as obesity, fasting plasma glucose > or =126 mg/dL, total cholesterol > or =240 mg/dL, triglyceride > or =150 mg/dL, and hyperuricemia, did not differ from that of subjects with normal ALT levels.
CONCLUSIONS: NAFLD is closely associated with elevated ALT, obesity, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, and hyperuricemia. Among the metabolic disorders, only hypertriglyceridemia was related to NAFLD in nonobese subjects. Serum ALT level was not a good predictor of metabolic significance in subjects with NAFLD.

Entities:  

Mesh:

Year:  2006        PMID: 16940890     DOI: 10.1097/00004836-200609000-00016

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  79 in total

1.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

Review 2.  Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.

Authors:  Mazen Noureddin; José M Mato; Shelly C Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-13

3.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

4.  Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study.

Authors:  Elizabeth K Speliotes; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; James B Meigs; Dushyant V Sahani; Joel N Hirschhorn; Christopher J O'Donnell; Caroline S Fox
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

Review 5.  Nonalcoholic fatty liver disease in Asia: emerging perspectives.

Authors:  Wai-Kay Seto; Man-Fung Yuen
Journal:  J Gastroenterol       Date:  2016-09-16       Impact factor: 7.527

6.  Frequency and implication of focal fatty sparing in segmental homogeneous fatty liver at ultrasound.

Authors:  Size Wu; Rong Tu; Guangqing Liu
Journal:  J Med Ultrason (2001)       Date:  2013-04-12       Impact factor: 1.314

7.  Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia.

Authors:  Seok-Chin Goh; Evelyn Lai-Ming Ho; Khean-Lee Goh
Journal:  Hepatol Int       Date:  2012-03-23       Impact factor: 6.047

Review 8.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 9.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

10.  Protective effect of probucol on liver injury induced by carbon tetrachloride in rats.

Authors:  Yu-Tao Zhan; Jing Weng; Li Li; Qing Xu; Xin Song; Xiao-Xia Guo
Journal:  Hepatol Int       Date:  2011-02-10       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.